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Introduction
Organophosphorus pesticides (OPs) are a class 
of insecticides that act by irreversibly inacti-
vating acetylcholinesterase, causing a build-up 
of acetylcholine in the synapse that leads to 
uncontrolled activation of sodium ion channel 
receptors (Fukuto 1990). Acute OP toxicity 
results from this acetylcholinesterase inhibi-
tion; however, biological effects of chronic 
low-dose exposure may not be mediated 
by this pathway (Ray and Richards 2001), 
and these alternate mechanisms have been 
shown to result in persistent behavioral and/
or neurocognitive deficits in animals (Icenogle 
et al. 2004; Levin et al. 2002; Ricceri et al. 
2003; Timofeeva et al. 2008; Vatanparast 
et al. 2013). Paraoxonase 1 (PON1), an 
antioxidant, is a key enzyme that deactivates 
certain OPs (Costa et al. 2003). The first 
metabolism step, mediated primarily by P450 
enzymes, converts the organothiophosphate to 
an oxon, the biologically active form, which 
PON1 then hydrolizes (Costa et al. 2003). 
Some functional polymorphisms in PON1 
have been extensively studied and correlate 
strongly with enzyme expression levels (–108 
C/T, T having reduced enzyme expression) or 
substrate-specific catalytic efficiency (Q192R, 
Q having slower catalytic efficiency for the 
chlorpyrifos oxon) (Costa et al. 2003).
Before 2001, residential applications 
of OPs to control pests were common 
in the United States particularly in urban, 
multi-housing units. In July 2000, the 
Environmental Protection Agency (EPA) 
and Dow Chemical agreed to eliminate all 
residential use of chlorpyrifos in the United 
States by 31 December 2001. In December 
2000, the U.S. EPA and registrants agreed to 
phase out and eliminate all indoor residential 
uses of diazinon by 31 December 2002 (U.S. 
EPA 2000, 2001). Diet from conventionally 
grown produce continues to be an important 
route of exposure in the general population to 
these and other OPs. Although OP pesticides 
continue to be widely used in agriculture, 
their usage has decreased over the last few 
decades—from 225 million pounds in 1980 
to < 100 million pounds in 2007 (Grube 
et al. 2011); this decline is consistent with 
biomonitoring data, which show a decline in 
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Background: Organophosphorus pesticides (OPs) are used in agriculture worldwide. Residential 
use was common in the United States before 2001.
oBjectives: We conducted a pooled analysis of four birth cohorts (children’s centers; n = 936) to 
evaluate associations of prenatal exposure to OPs with child development at 24 months.
Methods: Using general linear models, we computed site-specific and pooled estimates of the 
association of total dialkyl (∑DAP), diethyl (∑DEP), and dimethylphosphate (∑DMP) metabolite 
concentrations in maternal prenatal urine with mental and psychomotor development indices 
(MDI/PDI) and evaluated heterogeneity by children’s center, race/ethnicity, and PON1 genotype.
results: There was significant heterogeneity in the center-specific estimates of association for 
∑DAP and ∑DMP and the MDI (p = 0.09, and p = 0.05, respectively), as well as heterogeneity 
in the race/ethnicity-specific estimates for ∑DAP (p = 0.06) and ∑DMP (p = 0.02) and the 
MDI. Strong MDI associations in the CHAMACOS population per 10-fold increase in ∑DAP 
(β = –4.17; 95% CI: –7.00, –1.33) and ∑DMP (β = –3.64; 95% CI: –5.97, –1.32) were influ-
ential, as were associations among Hispanics (β per 10-fold increase in ∑DAP = –2.91; 95% CI: 
–4.71, –1.12). We generally found stronger negative associations of ∑DAP and ∑DEP with the 
24-month MDI for carriers of the 192Q PON1 allele, particularly among blacks and Hispanics.
conclusions: Data pooling was complicated by center-related differences in subject characteristics, 
eligibility, and changes in regulations governing residential use of OPs during the study periods. 
Pooled summary estimates of prenatal exposure to OPs and neurodevelopment should be inter-
preted with caution because of significant heterogeneity in associations by center, race/ethnicity, 
and PON1 genotype. Subgroups with unique exposure profiles or susceptibilities may be at higher 
risk for adverse neurodevelopment following prenatal exposure.
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median urinary OP metabolite levels over a 
6-year period in a representative sample of the 
U.S. general population (Barr et al. 2011). 
Nonetheless, residents in agricultural areas 
can be exposed if employed in agriculture, or 
by take-home exposure on clothes or shoes 
from household agricultural workers and by 
pesticide drift (Curl et al. 2002).
Starting in 1998, the National Institute 
o f  Env i ronmenta l  Hea l th  Sc i ence s 
(NIEHS) and EPA jointly funded multiple 
Children’s Environmental Health and 
Disease Prevention Research Centers across 
the United States. Four Centers pursued 
research on prenatal exposure to OP insec-
ticides: Columbia University (“Columbia”), 
Mount Sinai Medical Center (“Mount 
Sinai”), University of California at Berkeley 
CHAMACOS study (“CHAMACOS”), all 
starting in 1998, and Cincinnati Children’s 
Hospital HOME Study (“HOME”) starting 
in 2003. These four centers targeted urban 
(Mount Sinai and Columbia), urban and 
suburban (HOME), and rural/agricultural 
(CHAMACOS) populations, of varying 
sociodemographic and racial/ethnic charac-
teristics. Uniform biomarkers of exposure 
and metabolism and neurodevelopmental 
assessments were employed. Because indi-
vidual centers had limited power to explore 
associations within susceptible subgroups, 
we describe a pooled analysis of these four 
cohorts in relation to the mental and psycho-
motor development of children 24 months 
of age, taking into account both genetic and 
demographic susceptibility factors.
Methods
The enrollment criteria and procedures 
used by each center are described below and 
summarized in Table 1:
Study populations. The University 
of  Cal i fornia,  Berkeley,  Center  for 
Environmental Research and Children’s 
Health.  Between October 1999 and 
October 2000, the Center for the Health 
Assessment of Mothers and Children of 
Salinas (CHAMACOS) study enrolled 601 
pregnant women living in the Salinas Valley 
of California and receiving prenatal care 
at the Natividad Medical Center or one of 
five prenatal care clinics serving farmworker 
populations. Eligible women were < 20 weeks’ 
gestation at enrollment, were eligible for 
Medi-Cal, were ≥ 18 years of age, spoke 
English or Spanish, and planned to deliver 
at the Natividad Medical Center. Prenatal 
maternal spot urine specimens were obtained 
at enrollment on average at 13 weeks gesta-
tion and again at 26 weeks gestation. There 
were 538 infants after subtracting losses due 
to miscarriage, moving, or dropping from the 
study before delivery. Subsequent exclusions 
included gestational or preexisting diabetes, 
hypertension, twin births, stillbirths, and 
one very low birth weight infant (< 500 g), 
resulting in a final sample size of 488 preg-
nancies (Eskenazi et al. 2004). The Bayley 
Scales of Infant Development, 2nd Edition 
(BSID-II) was administered to children in 
Spanish and/or English by psychometricians 
who were unaware of the child’s exposure 
level (n = 372). The BSID-II is a standardized 
developmental test that assesses current devel-
opmental functioning and generates a Mental 
Development Index (MDI) and Psychomotor 
Developmental Index (PDI) (Bayley 1993). 
Together these describe the child’s current 
level of cognitive, language, and fine and 
gross motor development. Psychometricians 
were trained using standardized protocols 
and were supervised for quality assurance 
by a clinical neuropsychologist. Assessments 
were performed in a private room at the 
CHAMACOS research office or in a recre-
ational vehicle modified to be a mobile testing 
facility (Eskenazi et al. 2007).
Cincinnati Children’s Environmental 
Health Center HOME Study. The Health 
Outcomes and Measures of the Environment 
(HOME) Study enrolled a total of 468 
women between March 2003 and January 
2006. Because the HOME Study contains 
a nested, randomized trial of in-home lead 
and injury hazard controls, women had to 
have been living in housing built before 
1978. Additional eligibility criteria included 
< 19 weeks gestation upon enrollment; living 
in Brown, Butler, Clermont, Hamilton, or 
Warren counties in Ohio; intention to 
continue prenatal care and deliver at collabo-
rating obstetric practices; HIV negative; 
and not receiving seizure, thyroid, or 
chemotherapy/radiation medications. From 
these women, prenatal urine specimens were 
obtained at approximately 16 and 26 weeks 
gestation. A total of 389 women delivered live-
born, singleton infants without birth defects. 
The BSID-II was administered to 236 of these 
children at 24 months in a clinic setting by 
one of three examiners who were trained to 
reliability, and recertified in administration 
and scoring every 6 months. Examiners were 
blind to the exposure characteristics of the 
children (Chen A et al. 2014).
The Columbia Center for Children’s 
Environmental Health. The Columbia study 
enrolled 727 pregnant women between 
1998 and 2006. The cohort was restricted to 
nonsmoking women 18–35 years old who 
self-identified as either African-American race 
or Dominican ethnicity, and who had resided 
in Northern Manhattan or the South Bronx 
Table 1. Summary of study design characteristics by cohort.
Subject characteristics
UC Berkeley Center for Environmental 
Research and Children’s Health 
CHAMACOS Cohort 
Cincinnati Children’s 
Environmental Health Center 
HOME Study 
Columbia Center for Children’s 
Environmental Health Cohort
Mount Sinai Children’s 
Environmental Health and Disease 
Prevention Research Center Cohort
Study location & 
source population
Agricultural population in the 
Salinas Valley, California
Urban and suburban population 
residing in Brown, Butler, 
Clermont, Hamilton, or Warren 
counties in Ohio
Urban population residing 
in South Bronx or Northern 
Manhattan in New York City
Urban population consisting of women 
receiving antenatal care at the Mount 
Sinai Hospital or two private obstetric 
practices on the Upper East Side of 
Manhattan, New York City
Years of enrollment 1999–2000 2003–2006 2000–2001 1998–2002
Eligibility criteria Receiving prenatal care at a 
designated clinic; < 20 weeks’ at 
enrollment; eligible for medical; 
18 years or older; English or 
Spanish speaking
Living in housing built before 
1978; < 19 weeks gestation at 
enrollment
African-American or Dominican 
women; 18–35 years of 
age; first prenatal care visit 
< 20 weeks gestation
Primiparous; English or Spanish speaking; 
first prenatal care visit < 26 weeks 
gestation.
Exclusion criteria Twins; gestational or preexisting 
diabetes; hypertension; stillbirths; 
birth weight < 500 g 
Twins; HIV positive; 
receiving seizure, thyroid, 
or chemotherapy/radiation 
medications
Twins; diabetes; hypertension; 
known HIV infection; smoking; 
Illicit drug use
Twins; diabetes, hypertension or thyroid 
diseases; Illicit drug use or alcohol abuse 
during pregnancy; severe pregnancy 
complications including very premature 
birth (< 32 weeks or < 1,500 g at 
delivery); congenital malformations
Exposure measurement 2 urine samples at 13 and 26 weeks 
gestation averaged on a creatinine-
corrected basis
2 urine samples at 16 and 
26 weeks gestation averaged on 
a creatinine-corrected basis
1 urine sample at 32 weeks 
gestation
1 urine sample at 31 weeks gestation
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in New York City for > 1 year before preg-
nancy. Women were excluded if they reported 
illicit drug use; had diabetes, hypertension, 
or known HIV; or had their first prenatal 
visit after gestational week 20. Women were 
considered fully enrolled if a 48-hr personal 
air sample and a blood sample was obtained 
either from the mother during her third 
trimester or from cord blood at delivery. The 
Columbia study used a blood-based biomarker 
of chlorpyrifos as the primary dosimeter of 
exposure in their population (Whyatt et al. 
2004); however, from a subset of 91 women 
enrolled in 2000 and 2001, a maternal 
urine sample was obtained in the late third 
trimester (32.4 weeks; SD = 3.0) and analyzed 
for urinary OP biomarkers. Among these 91 
women, the BSID-II was administered to 63 
children in a study office by one of five trained 
bilingual research assistants who were assessed 
for reliability and blinded to exposure status. 
Every effort was made to maximize reliability 
in scoring by using standardized training 
procedures and regular quality control (Rauh 
et al. 2006).
T h e  M o u n t  S i n a i  C h i l d r e n ’ s 
Environmental  Health and Disease 
Prevention Research Center (Mount Sinai). 
The Mount Sinai study enrolled 479 primipa-
rous women with singleton pregnancies 
from the Diagnosis and Treatment Center 
prenatal clinic and two adjacent private 
practices between 1998 and 2002. Women 
were excluded if they had their first prenatal 
visit after 26 weeks of gestation; had chronic 
diseases such as diabetes, hypertension, or 
thyroid disease or developed a serious preg-
nancy complication that could affect fetal 
growth and development; and consumed 
more than two alcoholic beverages per day 
or who used illegal drugs (Berkowitz et al. 
2003). Seventy-five women were subsequently 
excluded because of medical complications, 
very premature births (< 32 weeks gesta-
tion or < 1,500 g), delivery of an infant with 
congenital malformations, inability to obtain 
biological specimens before delivery, change of 
residence, or refusal to continue participation 
(Engel et al. 2007). Prenatal maternal spot 
urine specimens were obtained in the third 
trimester (mean = 31.2 weeks, SD = 3.7). 
Birth data were available for 404 mother–
infant pairs. The BSID-II was administered 
to 225 of these children in English or Spanish 
at the study office by a trained examiner who 
was unaware of their exposure level and was 
supervised by a developmental psychologist. 
All examinations were scored by two indepen-
dent examiners, and any discrepancies were 
resolved by discussion and review of materials 
(Engel et al. 2011).
Biomarkers of OP exposure. For all studies, 
maternal urine samples were analyzed at the 
Centers for Disease Control and Prevention 
(CDC; Atlanta, GA) for six dialkylphosphate 
metabolites (including three diethylphosphate 
metabolites and three dimethylphosphate 
metabolites). CHAMACOS, Columbia, and 
Mount Sinai urine samples were analyzed 
at the CDC in 2002–2003, and those from 
the HOME study in 2010. Laboratory and 
quality control methods have been previ-
ously reported (Barr et al. 2005; Bravo et al. 
2004). For the CHAMACOS and HOME 
studies where two prenatal urine samples 
were obtained, the average of the creatinine-
corrected log10 urinary metabolite values was 
used as the best estimate of prenatal exposure. 
For the Mount Sinai and Columbia studies, 
only one prenatal urine sample was obtained. 
In cases where concentrations of individual 
metabolites were below the limit of detection 
(LOD) and an instrument-read value was not 
provided, a random value < LOD was imputed 
using maximum likelihood estimation based 
on a log-normal distribution truncated at 
the LOD. For samples in which a metabo-
lite value was missing due to analytic inter-
ference (n = 23), the missing value within a 
class (diethyl or dimethyl) was imputed using 
the other non-missing values within that 
class, as has been previously described (Engel 
et al. 2007; Eskenazi et al. 2004). A complete 
description of the proportion of urines with 
biomarker values below the LOD or missing 
due to analytic interference is presented in 
Supplemental Material, Table S1. Diethyl 
and dimethylphosphate metabolites were 
then summed on a molar basis to obtain total 
diethylphosphate (∑DEP) and total dimethyl-
phosphate (∑DMP) biomarker concentra-
tions, respectively, which were subsequently 
summed to obtain total dialkylphosphate 
(∑DAP) levels. Individual metabolites were 
corrected for urinary dilution by dividing by 
urinary creatinine concentrations before aver-
aging (CHAMACOS and HOME) and then 
summing (all cohorts). Urine specimens that 
contained < 10 mg/dL of creatinine (n = 4) 
were not used in the analysis. Summed metab-
olite concentrations that were extremely low 
(e.g., the sum of three metabolites < LOD) 
were truncated at 3 SDs below the geometric 
mean to avoid including influentially 
low values.
PON1 genotyping. We used existing 
cord blood PON1 –108C/T and Q192R 
polymorphism information from each of 
the centers. Although maternal PON1 geno-
types were available for some cohorts, they 
were not available for all. DNA extraction 
and genotyping methods have been previ-
ously described for the Mount Sinai (Chen J 
et al. 2003, 2005; Wetmur et al. 2005), 
CHAMACOS (Holland et al. 2006), and 
HOME populations (Rauch et al. 2012). 
For the Columbia cohort, child DNA was 
obtained from cord blood and genotyped for 
the –108C/T and Q192R polymorphism 
using TaqMan.
Statistical analyses. Potential confounders 
were identified a priori after inspection 
of directed acyclic graphs (not shown) 
and included center (nominal categorical), 
maternal education (nominal categorical: 
< high school, high school, any college), 
marital status (nominal categorical: single 
vs. married/living with partner), and race/
ethnicity (nominal categorical: white, 
black, Hispanic, other), smoking, alcohol 
or drug use during pregnancy (nominal 
categorical: ever/never), birth before 2001 
(nominal categorical), and the quality of 
the home environment as assessed by the 
Home Observation for Measurement of 
the Environment score (categorical: center-
specific quartiles) (Caldwell and Bradley 
1984). Gestational age at delivery and birth 
weight were not evaluated for confounding 
because they are potentially causal interme-
diates. We additionally considered adjusting 
for examiner, language spoken in the home 
(English, Spanish, other), child sex, and any 
breastfeeding for at least 3 months (ever/
never) if these variables improved the overall 
model precision. In comparing demographic 
and enrollment characteristics by center, it 
became clear that although these adjustment 
sets were desirable, they were not possible 
due to non-positivity (Cole and Hernán 
2008). Non-positivity occurs when there 
is a lack of exposed and unexposed indi-
viduals at every combination of the values 
of the confounders under study (Cole and 
Hernán 2008; Westreich and Cole 2010). In 
this case, conflicting enrollment and exclu-
sion and inclusion criteria resulted in centers 
with no participants in one or more levels of 
a potential confounders (e.g., race/ethnicity, 
smoking or drug use during pregnancy, birth 
before 2001, language spoken in the home, 
and Bayley examiner), which prevented us 
from implementing a fully adjusted model 
while simultaneously accounting for center. 
We therefore approached this analysis as 
follows: First we assessed center-related 
heterogeneity by including interaction terms 
for Center and ∑DAP/∑DEP/∑DMP in a 
model that included maternal education and 
marital status, alcohol use during pregnancy, 
child sex, Caldwell Home environment score, 
and breastfeeding for at least 3 months, using 
general linear models (SAS PROC GLM; SAS 
Institute Inc.). We also inspected the dose-
response function of log10 ∑DAP and the 
MDI using restricted cubic splines to deter-
mine the best exposure variable form. Spline 
modeling was done using the RCS REG SAS 
Macro with knots at the 20%, 50%, and 80% 
quantiles (Desquilbet and Mariotti 2010). 
We selected the best exposure functional form 
by considering the significance of the spline 
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terms using a 1-df (degree of freedom) Wald 
chi-square test (α = 0.05) (Desquilbet and 
Mariotti 2010), and the overall model Akaike 
information criterion (AIC) (favoring the 
model with the lowest AIC).
We next assessed heterogeneity by race/
ethnicity using an expanded model which 
additionally included smoking and drug use 
during pregnancy, but not center, because 
center and race/ethnicity, smoking, and drug 
use during pregnancy could not be simultane-
ously adjusted for in a regression model due to 
non-overlapping distributions in these factors 
by center. We then assessed whether any race/
ethnicity-specific associations varied by center 
by examining center-related heterogeneity 
within race/ethnicity groups.
Finally, to calculate an overall pooled 
association, we implemented linear mixed 
models in PROC MIXED, with a random 
intercept for center or race/ethnicity alter-
nately. We additionally examined whether 
including Bayley examiner as a random effect 
along with center substantially improved the 
overall model fit. Finally, we assessed inter-
actions with child PON1 genotype (three-
level categorical) overall and stratified by 
race/ethnicity (white, black, Hispanic). We 
considered all interactions to be significant at 
p < 0.10 using an F-test with 2 df. For main 
effects, we calculated 95% confidence inter-
vals (CIs) and examined the magnitude of 
the point estimate, the width of the interval, 
as well as whether the interval crossed the 
null value. All analyses were conducted in 
SAS version 9.3. All subjects provided written 
informed consent at baseline and follow-up 
and institutional review board approval was 
obtained by the University of North Carolina 
at Chapel Hill, the Mount Sinai Medical 
Center, the Cincinnati Children’s Hospital 
Medical Center, the University of California 
at Berkeley Committee for the Protection 
of Human Subjects, and the Columbia 
University Medical Center.
Results
Participant characteristics by center. We 
present participant characteristics by 
center in Table 2. Maternal education was 
lowest among CHAMACOS participants, 
and highest among HOME participants. 
Hispanics made up the majority of partici-
pants from the CHAMACOS and Mount 
Sinai centers, although Mount Sinai also 
enrolled a substantial number of white and 
black participants. All Columbia participants 
reported black race, but 40% reported their 
country of origin as the Dominican Republic; 
these participants were classified as Hispanic 
in this analysis. The majority of HOME 
participants were white, although there were 
also black and Hispanic participants enrolled.
Exposure dis tributions  by center . 
Prenatal urinary ∑DAP, ∑DEP, and ∑DMP 
biomarker concentrations can be found in 
Figure 1; see also Supplemental Material, 
Tables S1 and S2. Geometric mean ∑DAP 
and ∑DMP concentrations were substantially 
higher in the CHAMACOS cohort than in all 
other cohorts, whereas the ∑DEP exposure 
distributions were fairly similar across cohorts.
Twenty-four–month mental development 
index. The overall pooled dose–response 
function is consistent with a log10 linear 
term, although above approximately 2 nmol/g 
creatinine there is a leveling off, in large part 
due to a deviation in dose–response functions 
among cohorts, with HOME and Columbia 
demonstrating positive associations above 
that exposure level, whereas CHAMACOS 
Table 2. Distribution of demographic characteristics in individual cohorts.
Subject characteristics
UC Berkeley 
CHAMACOS Cohort  
(N = 377)
Cincinnati Children’s 
HOME Study  
(N = 265)
Columbia University  
(N = 60)
Mount Sinai School 
of Medicine  
(N = 234)
n Percent n Percent n Percent n Percent
Born before 2001 246 65.3 0 0 24 40 211 90.2
Maternal education
Less than high school 304 80.6 20 7.6 23 38.3 67 28.6
High school graduate/GED 36 9.6 26 9.8 20 33.3 48 20.5
Any college 37 9.8 219 82.6 17 28.3 119 50.8
Language spoken in homea
English 17 4.5 252 95.1 46 76.7 195 83.3
Any Spanish 356 94.4 0 0 10 16.7 38 16.2
Other 4 1.1 0 0 1 1.7 1 0.4
Maternal marital statusb
Not married/not living with partner 65 17.2 40 15.1 45 75.0 113 48.3
Married/living with partner 312 82.8 225 84.9 15 25.0 121 51.7
Parity
Nulliparous 116 30.8 115 43.4 30 50.0 234 100.0
Parous 261 69.2 150 56.6 30 50.0 0 0
Maternal country of origin
Other 332 88.1 15 5.7 24 40.0 41 17.5
USA 45 11.9 250 94.3 36 60.0 162 69.2
Maternal race/ethnicity
White 3 0.8 190 71.7 0 0 51 21.8
Black 0 0 59 22.3 36 30.0 57 24.4
Hispanic 369 97.9 5 1.9 24 40.0 123 52.6
Other 5 1.3 11 4.2 0 0 3 1.3
Maternal age at delivery (years)c 377 26.5 (5.2) 265 29.9 (5.3) 60 24.7 (5.2) 234 23.8 (6.5)
Any alcohol use during pregnancy 90 23.9 125 47.2 9 15.0 29 12.4
Any illicit drug use during pregnancy 6 1.6 12 4.5 0 0 15 6.4
Any smoking during pregnancy 18 4.8 26 9.8 0 0 39 16.7
Child sex
Male 185 49.1 122 46.04 18 30.0 126 53.9
Female 192 50.9 143 53.96 42 70.0 108 46.2
Breastfeeding at 3 months 273 72.4 167 63.02 37 61.7 101 43.2
24-month Psychomotor Development Index (PDI)c 377 97.6 ± 10.5 264 91.1 ± 14.0 60 94.5 ± 9.4 228 93.6 ± 11.6
24-month Mental Development Index (MDI)c 377 85.8 ± 11.7 265 89.6 ± 14.3 60 84.4 ± 11.9 234 87.9 ± 13.8
aFor Mount Sinai, primary language indicates the subject’s endorsement (n = 139), or when missing, the language in which the questionnaires were administered over the course of the 
study (n = 95). bColumbia required “living with a partner” to include only those who cohabited for ≥ 7 years. cMean ± SD.
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and Mount Sinai both found negative asso-
ciations. Nonetheless, a formal investiga-
tion of the suitability of a log10 linear term 
using a 1-df Wald chi-square test (α = 0.05) 
(Desquilbet and Mariotti 2010) did not 
reject linearity in the overall pooled exposure 
variable (Figure 2). All estimates are expressed 
per 10-fold increase in creatinine-corrected 
log10-transformed ∑DAP/DEP/DMP.
In a model adjusted for center, maternal 
education, marital status, maternal age at 
delivery, alcohol use during pregnancy, child 
sex, Caldwell Home environment score, and 
breastfeeding, there was significant hetero-
geneity by center in the association between 
∑DMP and ∑DAP and the MDI (p = 0.05 
and p = 0.09, respectively) (Table 3). 
CHAMACOS, Columbia, and Mount Sinai 
found negative associations between increasing 
∑DAP exposure and the MDI, whereas the 
HOME study found a positive association. 
Only the CHAMACOS center-specific asso-
ciation reached statistical significance. In 
CHAMACOS, the MDI score at 24 months 
declined by 4.17 points per 10-fold increase 
in creatinine-corrected, log10 transformed 
∑DAP (∑DAP β  = –4.17;  95% CI: 
–7.00, –1.33). The overall pooled association 
was also negative (∑DAP β = –1.28; 95% CI: 
–2.58, 0.03), and stronger after adjustment 
for maternal race/ethnicity, smoking, and 
drug use during pregnancy (∑DAP β = –1.48; 
95% CI: –2.77, –0.19), although technically 
the inclusion of these covariates violates the 
positivity assumption. Nonetheless, significant 
heterogeneity in the center-specific associa-
tions limits the interpretability of the pooled 
estimates. This heterogeneity was driven in 
large part by the strong negative associa-
tion in the CHAMACOS cohort. With the 
CHAMACOS population removed, the 
overall pooled association was attenuated 
(∑DAP β = –0.71; 95% CI: –2.25, 0.83). 
Overall, the heterogeneity evident in the 
center-specific associations argues against 
interpreting the pooled association.
We also explored heterogeneity in the 
pooled associations with MDI according to 
race/ethnicity without adjustment for center 
(Table 4). There was significant heterogeneity 
in the ∑DAP and ∑DMP associations with 
the MDI by race/ethnicity (p = 0.06 and 
p = 0.02, respectively), with the strongest 
negative associations found among Hispanics 
for ∑DAP and ∑DMP (∑DAP β = –2.91; 
95% CI: –4.71, –1.12; ∑DMP β = –2.34; 
95% CI: –3.77, –0.91). The CHAMACOS 
population accounted for approximately 
70% of all Hispanics included in this pooled 
analysis. Across racial/ethnic groups, the overall 
pooled association was still negative (∑DAP 
β = –1.39; 95% CI: –2.67, –0.10), although 
this was to a large degree driven by the strong 
negative association among Hispanics.
We also examined heterogeneity of the 
associations with MDI by the child PON1 
–108C/T and PON1 Q192R polymorphisms, 
in the whole population and within subgroups 
of race/ethnicity (Table 5). There was no signif-
icant heterogeneity attributable to the –108 
C/T polymorphism in the whole population 
for the ∑DAP, ∑DEP, or ∑DMP metabo-
lites. However, among whites there was signifi-
cant heterogeneity in estimates by genotype 
category, albeit in an unexpected direction. 
Although the T allele is considered the at-risk 
allele, corresponding to lower PON1 enzyme 
activity, white carriers of the TT genotype 
had higher MDI scores with increasing 
∑DAP exposure (∑DAP β = 5.35; 95% CI: 
–0.41, 11.11), whereas the associations in the 
CC and CT genotype categories were inverse, 
and all confidence intervals included the null 
value. Among blacks and Hispanics, no signifi-
cant heterogeneity by PON1 –108C/T was 
detected. There was a significant inter action 
with the Q192R polymorphism overall for 
∑DEP (p = 0.01), with inverse associations 
between exposure and MDI among carriers of 
the QR or QQ genotype, but not RR carriers. 
No significant heterogeneity was found overall 
for PON1 Q192R and ∑DAP or ∑DMP. 
Among blacks, there was significant hetero-
geneity between ∑DAP and PON1 Q192R 
(p = 0.08), although the confidence intervals 
were very imprecise. Inverse associations were 
found for carriers of the QR genotype, but not 
for the RR or QQ (at-risk) genotype.
In sensitivity analyses, we examined 
whether there was significant heterogeneity 
(at p < 0.10) in the ∑DAP/∑DEP/∑DMP 
associations among Hispanics from different 
cohorts, among whites from different cohorts, 
and among blacks from different cohorts, and 
found none (data not shown). We also found 
that adjustment for a prenatal lead exposure 
biomarker did not substantially improve the 
fit (by AIC), nor did exclusion of lead from 
the model confound any associations of OP 
metabolites with the MDI (data not shown). 
And finally, we explored whether the overall 
fit of the pooled mixed effects model was 
improved with the addition of Bayley examiner 
and found no substantial difference in the main 
effect estimates compared with those that do 
not include Bayley examiner (data not shown).
Twenty-four–month psychomotor develop-
ment index. Associations between OP metabo-
lites and the PDI were generally null at the 
24-month visit, with no indication that any 
associations were nonlinear, and with no 
substantial heterogeneity by center (Table 3), 
race/ethnicity (Table 4), or PON1 genotype 
(data not shown).
Figure 1. Distributions of dialkylphosphate metabolite sums in individual cohorts. The 25th, 50th, and 75th 
percentiles by center are represented by the lower, middle, and upper bars in the central boxes. The arith-
metic mean by center is marked by the open diamond. Outliers at the upper and lower end of the exposure 
distribution are indicated by circles. Whiskers indicate 95% CIs. 
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Discussion
In this pooled analysis of four prospectively 
enrolled NIEHS/EPA-funded Children’s 
Environmental Health and Disease Prevention 
Research Centers, we estimated that each 
10-fold increase in prenatal exposure to 
∑DAPs is associated with an approximate 
1-point decrease in the 24-month MDI, 
whether pooled across four cohorts without 
adjustment for race/ethnicity (β = –1.28; 
95% CI: –2.58, 0.03), or pooled across race/
ethnicities without adjustment for cohort 
(β = –1.48; 95% CI: –2.77, –0.19). Although 
the estimates in general lead to the same 
conclusion, they should both be interpreted 
with caution given that there was evidence 
of significant heterogeneity, particularly for 
the ∑DMP metabolites, that could in part be 
attributed to center and race/ethnicity, as well 
as a significant threat of residual confounding 
by factors exhibiting non-positivity across 
centers. As described above, non-positivity 
occurs when there is a lack of exposed and 
unexposed individuals at all levels of the 
observed confounders—in this case, differences 
in eligibility and enrollment criteria resulted 
in some centers that lacked study subjects at 
all levels of key covariates of concern (e.g., 
prenatal smoking and drug use, years of birth, 
language spoken in the home). We addition-
ally found evidence of heterogeneity in asso-
ciations by PON1 genotype. In particular, we 
found evidence of heterogeneity in associations 
of ∑DAPs with the MDI according to PON1 
–108C/T genotype among whites, hetero-
geneity with ∑DEPs and MDI according to 
PON1 Q192R in the whole population, and 
with ∑DAPs and PON1 Q192R among both 
whites and blacks. There was no evidence of an 
association with PDI.
Although in some respects these cohorts 
were ideally suited for pooling because of 
their similar data collection tools for covariate 
and outcome data and biomarker measures 
obtained from the same laboratory, there are 
also differences among these cohorts that 
limit the interpretability of the overall pooled 
estimates. Eligibility and enrollment charac-
teristics differed by center, as did the types 
of populations targeted (urban/suburban vs. 
agricultural) and the time frame of enroll-
ment. Although some of the study-specific 
exclusions are unlikely to present a bias in 
the absence of a strong association between 
exposure and the characteristic in question 
(e.g., smoking and parity), other differences 
present more cause for concern (e.g., target 
population, enrollment year, gestational age 
at delivery exclusions). Mount Sinai excluded 
births < 32 weeks or < 1,500 g, CHAMACOS 
Figure  2. Restricted cubic splines for log10 ∑DAP association with the 24-month MDI in the 
(A) CHAMACOS cohort, (B) HOME cohort, (C) Columbia cohort, (D) Mount Sinai cohort, and (E) pooled 
population. Splines demonstrate a roughly linearly declining relationship in the individual cohorts and the 
overall pooled population below approximately 2 nmol/g creatinine, which attenuates at higher concentra-
tions. Although the HOME (B) and Columbia (C) cohorts appear to show a U-shape curve, the 95% CIs 
(dashed lines) demonstrate substantial imprecision around these estimates.
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Table 3. Association of creatinine-corrected log10 prenatal OP metabolite levels and 24-month MDI and PDI considering heterogeneity by center.
Model
CHAMACOS  
[β per 10-fold 
increase (95% CI)]a
HOME  
[β per 10-fold 
increase (95% CI)]a
Columbia  
[β per 10-fold 
increase (95% CI)]a
Mount Sinai  
[β per 10-fold 
increase (95% CI)]a
Center-OP-
interaction 
(p-value)a
Pooled 
[β per 10-fold 
increase (95% CI)]a
Pooled (extended model) 
[β per 10-fold 
increase (95% CI)]b
24-month MDI n = 366 n = 257 n = 53 n = 225 n = 901 n = 901 n = 890
Log10 ∑DAP (nmol/gC) –4.17 (–7.00, –1.33) 0.97 (–1.82, 3.76) –0.79 (–4.17, 2.59) –1.14 (–3.12, 0.84) 0.09 –1.28 (–2.58, 0.03) –1.48 (–2.77, –0.19)
Log10 ∑DEP (nmol/gC) –1.40 (–4.12, 1.32) –1.10 (–3.42, 1.22) 0.11 (–2.88, 3.11) –0.22 (–1.85, 1.42) 0.81 –0.57 (–1.69, 0.54) –0.82 (–1.93, 0.28)
Log10 ∑DMP (nmol/gC) –3.64 (–5.97, –1.32) 0.73 (–1.59, 3.04) 0.13 (–2.33, 2.58) –0.80 (–2.52, 0.91) 0.05 –0.91 (–1.98, 0.16) –1.06 (–2.12, 0.00)
24-month PDI n = 368 n = 258 n = 55 n = 228 n = 909 n = 909 n = 898
Log10 ∑DAP (nmol/gC) –1.35 (–4.10, 1.41) 1.09 (–1.63, 3.80) –0.39 (–3.67, 2.90) –0.27 (–2.17, 1.63) 0.67 –0.23 (–1.48, 1.03) –0.08 (–1.34, 1.18)
Log10 ∑DEP (nmol/gC) –0.91 (–3.54, 1.72) –0.32 (–2.57, 1.93) –0.35 (–3.13, 2.42) 0.52 (–1.03, 2.06) 0.79 –0.02 (–1.09, 1.04) 0.15 (–0.91, 1.22)
Log10 ∑DMP (nmol/gC) –1.29 (–3.56, 0.97) 0.83 (–1.41, 3.08) –0.42 (–2.79, 1.95) –0.45 (–2.11, 1.21) 0.63 –0.35 (–1.39, 0.68) –0.30 (–1.34, 0.73)
∑DAP = ∑DEP + ∑DMP.
aModels were adjusted for maternal education, marital status, and age at delivery, alcohol use during pregnancy, child sex, Home environment score quartile, and breastfeeding at 
least 3 months after birth, and include metabolite × center interaction terms. Tests for interaction were calculated using F-tests with 3 degrees of freedom. bAdditionally adjusted for 
race/ethnicity, smoking and drug use during pregnancy.
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excluded births < 500 g, and Columbia 
measured exposure late in the third trimester 
of pregnancy, thus resulting in a truncated 
gestational age distribution that effectively 
excluded many preterm births. The Mount 
Sinai and Columbia populations individu-
ally found no associations between organo-
phosphorus pesticide exposures and length of 
gestation (Berkowitz et al. 2004; Whyatt et al. 
2005), but the HOME and CHAMACOS 
populations did, at least for some of the 
metabolites (Eskenazi et al. 2004; Rauch et al. 
2012). Although these were relatively weak 
associations overall, still, to the extent that 
early delivery lies intermediate on the causal 
pathway between exposure and neurodevelop-
ment, exclusions of very early deliveries may 
have to some extent biased estimates of asso-
ciations. We believe, however, that any bias is 
likely to be small given that on a population 
level, births < 32 weeks gestation or < 1,500 g 
account for < 1% of singleton births in the 
United States (Martin et al. 2015). Of more 
significance are cohort differences in target 
population and enrollment year, which are 
sure to have a pronounced impact on the type 
and intensity of parent OP exposures.
Another challenge to pooling these 
four unique cohorts was in reconciling the 
underlying exposure biomarker distributions. 
The distribution of the ∑DAP biomarkers 
was severely right skewed. And although 
the ∑DEP biomarker concentrations were 
very similar across the cohorts, the median 
∑DMP exposure biomarker concentrations 
were considerably higher in the CHAMACOS 
study than in the Mount Sinai (42% higher), 
HOME study (78% higher), and Columbia 
(256% higher) populations. The advantages 
of the log10 transformation in the presence 
of right skewed data include achieving a 
more normal distribution and reducing the 
impact of outliers in modeling. Moreover, the 
dose–response function in our pooled popula-
tion was consistent with a log10 linear term. 
Applying a log10 transformation to these data 
results in the expansion of values at the low 
end of exposure and the constriction of values 
at the high end of exposure. For example, an 
increase in exposure concentration from 0.9 
to 9.0 nmol/gC and from 9.0 to 90 nmol/gC 
both equate to a 1-log10 unit change. As a 
result, the absolute increase in exposure 
concentration implied by a change in log10 
units is relative to where you are in the natural 
distribution. This feature comprises the major 
limitation of the log10 transformation— 
specifically, the interpretability of effect esti-
mates in reference to an absolute change in 
exposure level is lost. This is particu larly prob-
lematic when comparing across centers with 
dissimilar exposure distributions. Moreover, it 
is possible that to some extent our findings of 
center and race-driven heterogeneity in asso-
ciations are in part a result of this transforma-
tion, in that the absolute change in biomarker 
concentration for the CHAMACOS study per 
log10 unit might be on average higher than the 
other centers, resulting in more elevated effect 
estimates in the CHAMACOS study.
Although DAP metabolites are the most 
commonly reported internal dosimeter of 
OP pesticide exposure, these biomarkers 
are nonspecific; the same metabolite can 
derive from multiple parent OPs that may 
differ in toxicity and potency. Therefore, a 
given DAP biomarker concentration from 
CHAMACOS, where subjects were exposed 
to pesticides used in agriculture as well as 
other sources of exposure (e.g., diet or resi-
dential use), may not mean the same thing 
Table 4. Association of creatinine-corrected log10 prenatal OP metabolite levels and 24-month MDI and PDI considering heterogeneity by race/ethnicity.
Model
White  
[β per 10-fold 
increase (95% CI)]a
Black  
[β per 10-fold 
increase (95% CI)]a
Hispanic  
[β per 10-fold 
increase (95% CI)]a
Race/ethnicity- 
OP interaction  
(p-value)a
Pooled  
[β per 10-fold 
increase (95% CI)]b
24-month MDI n = 231 n = 142 n = 499 n = 872 n = 890
Log10 ∑DAP (nmol/gC) –0.29 (–2.89, 2.31) 0.49 (–2.07, 3.05) –2.91 (–4.71, –1.12) 0.06 –1.39 (–2.67, –0.10)
Log10 ∑DEP (nmol/gC) –1.46 (–3.62, 0.69) 0.09 (–2.15, 2.33) –1.00 (–2.57, 0.58) 0.60 –0.82 (–1.92, 0.29)
Log10 ∑DMP (nmol/gC) –0.21 (–2.39, 1.98) 1.10 (–0.94, 3.14) –2.34 (–3.77, –0.91) 0.02 –0.97 (–2.00, 0.07)
24-month PDI n = 234 n = 144 n = 502 n = 880 n = 898
Log10 ∑DAP (nmol/gC) 2.34 (–0.21, 4.88) –0.47 (–2.97, 2.03) –0.41 (–2.18, 1.37) 0.18 0.26 (–1.00, 1.51)
Log10 ∑DEP (nmol/gC) 1.15 (–0.97, 3.27) –0.57 (–2.75, 1.62) 0.27 (–1.24, 1.78) 0.54 0.32 (–0.75, 1.40)
Log10 ∑DMP (nmol/gC) 1.62 (–0.52, 3.75) –0.12 (–2.15, 1.91) –0.53 (–1.95, 0.89) 0.25 0.06 (–0.96, 1.08)
∑DAP = ∑DEP + ∑DMP.
aModels were adjusted for maternal education, marital status and age at delivery, alcohol, drug use or smoking during pregnancy, child sex, quartiles of Home environment score, 
breastfeeding at least 3 months after birth, and birth before 2001, and include metabolite × race/ethnicity interaction terms. “Other” race/ethnicity was excluded due to small numbers. 
Tests for interaction were calculated using F-tests with 2 degrees of freedom. bPooled models include all race/ethnicity categories.
Table 5. Association of creatinine-corrected log10 prenatal OP metabolite levels and 24-month MDI according to PON1 genotype.
PON1 genotype
Pooled Blacks Whites Hispanics
n
Pooled β per 10-fold 
increase (95% CI)  
log10 ∑DAP  
(nmol/gC)a
Pooled β per 10-fold 
increase (95% CI)  
log10 ∑DEP 
(nmol/gC)a
Pooled β per 10-fold 
increase (95% CI)  
log10 ∑DMP 
(nmol/gC)a n
β per 10-fold  
increase (95%CI) 
log10 ∑DAP 
(nmol/gC)b n
β per 10-fold 
increase (95% CI)  
log10 ∑DAP 
(nmol/gC)b n
β per 10-fold 
increase (95% CI)  
log10 ∑DAP 
(nmol/gC)b
–108 C/T 766 11 203 429
CC 280 –2.35 (–4.58, –0.12) –0.61 (–2.55, 1.33) –1.78 (–3.59, 0.03) 75 –0.50 (–4.33, 3.32) 58 –5.12 (–10.71, 0.48) 140 –2.31 (–5.95, 1.32)
CT 346 –0.12 (–2.22, 1.97) –0.24 (–2.17, 1.69) –0.45 (–2.17, 1.26) 37 3.47 (–1.74, 8.68) 96 –0.37 (–4.30, 3.56) 207 –1.55 (–4.43, 1.32)
TT (at risk) 140 –1.22 (–4.48, 2.03) –1.74 (–4.56, 1.07) 0.14 (–2.34, 2.61) 7 –1.38 (–15.23, 12.47) 49 5.35 (–0.41, 11.11) 82 –5.54 (–9.67, –1.40)
p-Interaction 0.36 0.68 0.39 0.45 0.04 0.29
Q192R 762 112 206 429
RR 229 0.51 (–1.98, 3.01) 2.09 (–0.14, 4.31) 0.08 (–2.16, 2.32) 56 3.52 (–0.21, 7.26) 17 9.71 (–4.79, 24.22) 103 –3.86 (–7.97, 0.25)
QR 354 –2.31 (–4.60, –0.02) –1.94 (–3.94, 0.07) –1.23 (–2.86, 0.39) 47 –3.16 (–9.63, 3.32) 74 –4.10 (–8.69, 0.48) 224 –1.87 (–4.84, 1.09)
QQ (at risk) 179 –1.74 (–4.22, 0.75) –1.93 (–4.10, 0.24) –1.13 (–3.27, 1.02) 9 –11.85 (–25.51, 1.80) 115 1.15 (–2.53, 4.84) 102 –3.19 (–6.70, 0.33)
p-Interaction 0.23 0.01 0.62 0.04 0.08 0.71
∑DAP = ∑DEP + ∑DMP.
aModels were adjusted for maternal race/ethnicity, maternal education, age at delivery and marital status, smoking, alcohol or drug use during pregnancy, child sex, quartile of Home 
environment score, breastfeeding at least 3 months after birth, and birth before 2001, and include metabolite × genotype interaction terms. Tests for interaction were calculated 
using F-tests with 2 degrees of freedom. bModels were adjusted for maternal education, age at delivery and marital status, smoking, alcohol or drug use during pregnancy, child sex, 
quartile of Home environment score, breastfeeding at least 3 months after birth, and birth prior to 2001, and include metabolite × genotype interaction terms. Tests for interaction were 
calculated using F-tests with 2 degrees of freedom.
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as the same DAP biomarker concentration 
from the Mount Sinai or Columbia studies, 
which captured residential use of chlorpy-
rifos and diazinon during permissible periods, 
as well as dietary exposures. Although some 
parent compounds are used in both settings, 
others are not. It is, for example, plausible 
that the strong negative association observed 
between the dimethylphosphate metabolites 
and the MDI in the CHAMACOS popu-
lation is attributable partly to local use 
of oxydemeton-methyl, a highly toxic OP 
solely used in agriculture. Unfortunately, our 
pooled data do not permit definitive identifi-
cation of the parent compound mix to which 
a subject was exposed, and it is likely that the 
parent compound exposure composition is 
more similar across subjects within a given 
cohort than across cohorts.
Another important consideration is the 
relative contributions of parent compound 
exposures versus preformed DAP exposures. 
Direct exposure to parent OP pesticide 
compounds results in metabolism and the 
production of metabolites along with the 
biologically active oxon-form. However 
hydrolysis or photolysis of parent compounds 
present in food and the environment also 
generates preformed DAPs that are not toxic 
when consumed, and that are mostly excreted 
unchanged in urine (Chen L et al. 2012; 
Zhang et al. 2008). Thus, measurements of 
DAPs in urine may overestimate exposure to 
parent pesticide compounds.
Exposure to OP pesticides through the 
diet (Lu et al. 2005) may result in a higher 
fraction of preformed DAP exposure relative 
to parent compound exposure compared with 
exposure through direct OP pesticide applica-
tions (residentially or occupationally) or drift 
from nearby applications or para-occupational 
take-home exposures (Deziel et al. 2015; 
Quirós-Alcalá et al. 2012).
It is likely that the CHAMACOS popu-
lation, located in an agricultural region 
with heavy continuing OP pesticide use, 
received a more substantial fraction of parent 
compound exposure relative to the Mount 
Sinai, Columbia, or HOME populations. 
Furthermore, the HOME population, which 
was enrolled after the U.S. EPA moved to 
restrict residential uses of OPs, likely expe-
rienced higher dietary versus environmental 
exposures compared with the two New York 
City cohorts, which both spanned periods 
of indoor use of chlorpyrifos and diazinon 
for cockroaches. These circumstances likely 
resulted in the HOME study population 
having the highest fraction of preformed DAP 
exposures out of their total DAP exposure, 
and therefore those with higher urinary DAP 
biomarkers may have eaten higher quality 
diets that are high in fruits and vegetables. 
These differences in source, route, and 
period may partly account for the significant 
center-driven heterogeneity that we identi-
fied in our analysis (p = 0.09), although 
there is a lack of empirical evidence to fully 
describe any differences in exposure source 
and intensity the participants in these cohorts 
experienced. Indeed, the pattern of associa-
tions across the centers appears to accurately 
reflect our a priori expectations of the magni-
tude of parent compound exposures these 
subjects were likely to have experienced. The 
CHAMACOS association was the strongest 
(β = –4.17; 95% CI: –7.00, –1.33), followed 
by very similar estimates between the Mount 
Sinai (β = –1.14; 95% CI: –3.12, 0.84) and 
Columbia populations (β = –0.79; 95% CI: 
–4.17, 2.59), with a positive association in the 
Cincinnati HOME study (β = 0.97; 95% CI: 
–1.82, 3.76). The CHAMACOS population, 
an agricultural population where 44% of the 
study subjects reported personally working in 
agriculture during pregnancy and 84% lived 
with farmworkers, is likely to have experi-
enced the highest parent compound exposure 
burden. Mount Sinai and Columbia also were 
enrolled before the U.S. EPA action to limit 
residential exposures, so exposure to parent 
compounds was likely to have been similar 
between the two cohorts, although less than 
in the agriculturally exposed CHAMACOS 
cohort. And the HOME study, because of 
the geographic and sociodemographic groups 
enrolled and the time period of enrollment, 
was likely to have been exposed primarily 
through the diet, with the least direct parent 
compound exposure (Yolton et al. 2013). 
Therefore, although the same method of 
exposure assessment was employed in all four 
studies, the meaning of the biomarkers may 
differ across studies, so pooling may obscure, 
at least in part, important differences in 
 associations across studies.
Additionally, DAP biomarkers of OP 
exposure have been shown to exhibit low 
reproducibility over the course of pregnancy 
in a subset of the Generation R study, a 
 population-based cohort from the Netherlands, 
in which a major determinant of exposure level 
was found to be fruit intake (Spaan et al. 2015). 
Two of the cohorts included in this pooled 
analysis collected two urine samples during 
pregnancy (CHAMACOS and the HOME 
study), and the creatinine-corrected average of 
these two specimens was used, and two cohorts 
only collected urine samples in the third 
trimester. Classifying exposure based on the 
mean value in two samples (vs. one sample) is 
likely to reduce exposure misclassification due 
to high within-subject variability, but might 
obscure associations if effects are specific to a 
particular time window of exposure.
Other limitations of pooled analyses 
should be taken into consideration when 
weighing these results. Both confounder 
adjustment and an examination of hetero-
geneity in any OP associations by suscep-
tibility factors were limited to covariates 
and characteristics that were shared by all 
centers. This may have resulted in differences 
between previously reported center-specific 
associations, undetected but important effect 
heterogeneity, or the possibility of residual 
confounding by factors, such as poverty, 
prenatal smoking, primary language used 
in the home, parity, and other factors, that 
could not be accounted for due to non-
overlapping covariate distributions. Including 
such covariates into multivariable adjusted 
pooled models when the expected sample size 
for a given cohort is zero in that exposure-
covariate strata violates our assumption of 
positivity (Cole and Hernán 2008)—that 
at every level of the confounders there are 
both exposed and unexposed participants. 
For example, additionally adjusting for race/
ethnicity in a center-adjusted pooled model 
required that we assume that the effect of 
race is the same across each of the sites, an 
assumption that we could not explore for 
centers that lacked participants in one or 
more race/ethnicity group. Moreover, this 
assumption seemed tenuous given our knowl-
edge of the differences in the CHAMACOS 
exposure source profile compared with all 
other cohorts. The analogous assumption is 
perhaps easier to accept for other covariates 
such as prenatal smoking or multiparity. We 
were able to assess differences only in our 
cohort-specific associations (with limited 
covariate adjustment that was consistent 
across all studies) from previously published 
estimates for the CHAMACOS (Eskenazi 
et al. 2007) and the Mount Sinai studies 
(Engel et al. 2011). For the CHAMACOS 
study, our current beta estimate for DAP 
metabolites and the MDI was slightly 
elevated relative to the prior paper, and there 
were essentially no differences for the other 
metabolites, or for any metabolite and the 
PDI. There were more differences in magni-
tude evident when comparing the Mount 
Sinai beta estimates, the current analysis 
yielding somewhat attenuated associations. 
Additionally, although pooling these cohorts 
affords us more power to investigate gene–
environment interactions, our power was still 
limited, particularly when stratified by race/
ethnicity, to estimate stable associations in the 
rare genotype categories.
In conclusion, although it is important to 
determine whether there is an overall effect of 
OP exposure experienced in diverse settings 
on child neurodevelopment both for policy 
and for research purposes, a careful exami-
nation of the site-specific findings remains 
essential in understanding the implications 
of heterogeneity in exposure period, source, 
and susceptibility.
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830 volume 124 | number 6 | June 2016 • Environmental Health Perspectives
RefeRences
Barr DB, Allen R, Olsson AO, Bravo R, Caltabiano LM, 
Montesano A, et al. 2005. Concentrations of selec-
tive metabolites of organophosphorus pesticides 
in the United States population. Environ Res 
99(3):314–326.
Barr DB, Wong LY, Bravo R, Weerasekera G, 
Odetokun  M, Restrepo P, et  al. 2011. Urinary 
concentrations of dialkylphosphate metabolites 
of organophosphorus pesticides: National Health 
and Nutrition Examination Survey 1999–2004. Int J 
Environ Res Public Health 8(8):3063–3098.
Bayley N. 1993. Bayley Scales of Infant Development. 
2nd ed. San Antonio, TX:Harcourt Brace & Company.
Berkowitz GS, Obel J, Deych E, Lapinski R, Godbold J, 
Liu Z, et al. 2003. Exposure to indoor pesticides 
during pregnancy in a multiethnic, urban cohort. 
Environ Health Perspect 111:79–84, doi:10.1289/
ehp.5619.
Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, 
Lapinski RH, Godbold JH, et al. 2004. In utero pesti-
cide exposure, maternal paraoxonase activity, 
and head circumference. Environ Health Perspect 
112:388–391, doi:10.1289/ehp.6414.
Bravo R, Caltabiano LM, Weerasekera G, Whitehead RD, 
Fernandez C, Needham LL, et al. 2004. Measurement 
of dialkyl phosphate metabolites of organophos-
phorus pesticides in human urine using lyophili-
zation with gas chromatography-tandem mass 
spectrometry and isotope dilution quantification. J 
Expo Anal Environ Epidemiol 14(3):249–259.
Caldwell BM, Bradley RH. 1984. Administration 
Manual: Home Observation For Measurement 
of the Environment. Revised ed. Little Rock, 
AR:University of Arkansas at Little Rock.
Chen A, Yolton K, Rauch SA, Webster GM, Hornung R, 
Sjödin  A, et  al. 2014. Prenatal polybrominated 
diphenyl ether exposures and neurodevelopment 
in U.S. children through 5 years of age: the HOME 
Study. Environ Health Perspect 122:856–862, 
doi:10.1289/ehp.1307562.
Chen J, Chan W, Wallenstein S, Berkowitz G, 
Wetmur  JG. 2005. Haplotype-phenotype rela-
tionships of paraoxonase-1. Cancer Epidemiol 
Biomarkers Prev 14(3):731–734.
Chen J, Kumar M, Chan W, Berkowitz G, WetmurJG. 
2003. Increased influence of genetic variation 
on PON1 activity in neonates. Environ Health 
Perspect 111:1403–1409, doi:10.1289/ehp.6105.
Chen L, Zhao T, Pan C, Ross JH, Krieger RI. 2012. 
Preformed biomarkers including dialkylphos-
phates (DAPs) in produce may confound biomoni-
toring in pesticide exposure and risk assessment. 
J Agric Food Chem 60(36):9342–9351.
Cole SR, Hernán MA. 2008. Constructing inverse prob-
ability weights for marginal structural models. 
Am J Epidemiol 168(6):656–664.
Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, 
Furlong CE. 2003. Paraoxonase (PON  1) as a 
biomarker of susceptibility for organophosphate 
toxicity. Biomarkers 8(1):1–12.
Curl CL, Fenske RA, Kissel JC, Shirai JH, Moate TF, 
Griffith W, et al. 2002. Evaluation of take-home 
organophosphorus pesticide exposure among 
agricultural workers and their children. Environ 
Health Perspect 110:A787–A792.
Desquilbet L, Mariotti F. 2010. Dose-response analyses 
using restricted cubic spline functions in public 
health research. Stat Med 29(9):1037–1057.
Deziel NC, Friesen MC, Hoppin JA, Hines CJ, 
Thomas K, Freeman LE. 2015. A review of nonoc-
cupational pathways for pesticide exposure in 
women living in agricultural areas. Environ Health 
Perspect 123:515–524, doi:10.1289/ehp.1408273.
Engel SM, Berkowitz GS, Barr DB, Teitelbaum SL, 
Siskind  J, Meisel SJ, et  al. 2007. Prenatal 
organophosphate metabolite and organochlo-
rine levels and performance on the Brazelton 
Neonatal Behavioral Assessment Scale in a 
multiethnic pregnancy cohort. Am J Epidemiol 
165(12):1397–1404.
Engel SM, Wetmur J, Chen J, Zhu C, Barr DB, 
Canfield  RL, et  al. 2011. Prenatal exposure to 
organophosphates, paraoxonase 1, and cogni-
tive development in childhood. Environ Health 
Perspect 119:1182–1188, doi:10.1289/ehp.1003183.
Eskenazi B, Harley K, Bradman A, Weltzien E, 
Jewell NP, Barr DB, et al. 2004. Association of 
in  utero organophosphate pesticide exposure 
and fetal growth and length of gestation in an 
agricultural population. Environ Health Perspect 
112:1116–1124, doi:10.1289/ehp.6789.
Eskenazi B, Marks AR, Bradman A, Harley K, Barr DB, 
Johnson C, et al. 2007. Organophosphate pesti-
cide exposure and neurodevelopment in young 
Mexican-American children. Environ Health 
Perspect 115:792–798, doi:10.1289/ehp.9828.
Fukuto TR. 1990. Mechanism of action of organo-
phosphorus and carbamate insecticides. Environ 
Health Perspect 87:245–254.
Grube A, Donaldson D, Kiely T, Wu L. 2011. Pesticides 
Industry Sales and Usage: 2006 and 2007 Market 
Estimates. EPA 733-R-11-001. Washington, DC:U.S. 
Environmental Protection Agency.
Holland N, Furlong C, Bastaki M, Richter R, Bradman A, 
Huen K, et al. 2006. Paraoxonase polymorphisms, 
haplotypes, and enzyme activity in Latino 
mothers and newborns. Environ Health Perspect 
114:985–991, doi:10.1289/ehp.8540.
Icenogle LM, Christopher NC, Blackwelder WP, 
Caldwell  DP, Qiao D, Seidler FJ, et  al. 2004. 
Behavioral alterations in adolescent and adult 
rats caused by a brief subtoxic exposure to chlor-
pyrifos during neurulation. Neurotoxicol Teratol 
26(1):95–101.
Levin ED, Addy N, Baruah A, Elias A, Christopher NC, 
Seidler  FJ, et  al. 2002. Prenatal chlorpyrifos 
exposure in rats causes persistent behavioral 
alterations. Neurotoxicol Teratol 24(6):733–741.
L u  C ,  B r a v o  R ,  C a l t a b i a n o  L M ,  I r i s h   R M , 
Weerasekera G, Barr DB. 2005. The presence of 
dialkylphosphates in fresh fruit juices: implica-
tion for organophosphorus pesticide exposure 
and risk assessments. J Toxicol Environ Health A 
68(3):209–227.
Martin JA, Hamilton BE, Osterman MJK, Curtin SC, 
Mathews TJ. 2015. Births: Final Data for 2013. Natl 
Vital Stat Rep 64(1):1–65.
Q u i r ó s - A l c a l á  L ,  B r a d m a n  A ,  S m i t h   K , 
Weerasekera  G, Odetokun M, Barr DB, et  al. 
2012. Organophosphorous pesticide breakdown 
products in house dust and children’s urine. 
J Expo Sci Environ Epidemiol 22(6):559–568.
Rauch SA, Braun JM, Barr DB, Calafat AM, Khoury J, 
Montesano  AM, et  al. 2012. Associations of 
prenatal exposure to organophosphate pesti-
cide metabolites with gestational age and birth 
weight. Environ Health Perspect 120:1055–1060, 
doi:10.1289/ehp.1104615.
Rauh VA, Garfinkel R, Perera FP, Andrews  HF, 
Hoepner L, Barr DB, et al. 2006. Impact of prenatal 
chlorpyrifos exposure on neurodevelopment in 
the first 3 years of life among inner-city children. 
Pediatrics 118(6):e1845–e1859.
Ray DE, Richards PG. 2001. The potential for toxic 
effects of chronic, low-dose exposure to organo-
phosphates. Toxicol Lett 120(1–3):343–351.
Ricceri L, Markina N, Valanzano A, Fortuna  S, 
Cometa  MF, Meneguz A, et  al. 2003. Develop-
mental exposure to chlorpyrifos alters reactivity to 
environmental and social cues in adolescent mice. 
Toxicol Appl Pharmacol 191(3):189–201.
Spaan S, Pronk A, Koch HM, Jusko TA, Jaddoe VW, 
Shaw PA, et al. 2015. Reliability of concentra-
tions of organophosphate pesticide metabolites 
in serial urine specimens from pregnancy in the 
Generation R Study. J Expo Sci Environ Epidemiol 
25(3):286–294.
Timofeeva OA, Roegge CS, Seidler FJ, Slotkin TA, 
Levin ED. 2008. Persistent cognitive alterations in 
rats after early postnatal exposure to low doses 
of the organophosphate pesticide, diazinon. 
Neurotoxicol Teratol 30(1):38–45.
U.S. EPA (U.S. Environmental Protection Agency). 
2000. Chlorpyrifos. Revised Risk Assessment and 
Agreement with Registrants. Washington, DC:U.S. 
EPA, Office of Pesticide Programs.
U.S. EPA. 2001. Diazinon Revised Risk Assessment and 
Agreement with Registrants. Washington DC:U.S. 
EPA, Office of Pesticide Programs.
Vatanparast J, Naseh M, Baniasadi M, Haghdoost-
Yazdi H. 2013. Developmental exposure to chlor-
pyrifos and diazinon differentially affect passive 
avoidance performance and nitric oxide synthase-
containing neurons in the basolateral complex of 
the amygdala. Brain Res 1494:17–27.
Westreich D, Cole SR. 2010. Invited commentary: posi-
tivity in practice. Am J Epidemiol 171(6):674–677.
Wetmur JG, Kumar M, Zhang L, Palomeque C, 
Wallenstein S, Chen J. 2005. Molecular haplo-
typing by linking emulsion PCR: analysis of para-
oxonase 1 haplotypes and phenotypes. Nucleic 
Acids Res 33(8):2615–2619.
Whyatt RM, Camann D, Perera FP, Rauh VA, Tang D, 
Kinney PL, et al. 2005. Biomarkers in assessing 
residential insecticide exposures during preg-
nancy and effects on fetal growth. Toxicol Appl 
Pharmacol 206(2):246–254.
Whyatt RM, Rauh V, Barr DB, Camann DE, Andrews HF, 
Garfinkel R, et  al. 2004. Prenatal insecticide 
exposures and birth weight and length among an 
urban minority cohort. Environ Health Perspect 
112:1125–1132, doi:10.1289/ehp.6641.
Yolton K, Xu Y, Sucharew H, Succop P, Altaye  M, 
Popelar A, et al. 2013. Impact of low-level gesta-
tional exposure to organophosphate pesticides on 
neurobehavior in early infancy: a prospective study. 
Environ Health 12(1):79, doi:10.1186/1476-069X-12-79.
Zhang X, Driver JH, Li Y, Ross JH, Krieger RI. 2008. 
Dialkylphosphates (DAPs) in fruits and vegetables 
may confound biomonitoring in organophosphorus 
insecticide exposure and risk assessment. J Agric 
Food Chem 56(22):10638–10645.
